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Fluorescent antibody studies have revealed Shope papilloma viral antigens in 
the nuclei of the keratinized and keratohyalinized layers of both the cottontail 
and  domestic  rabbit  papillomas  (1,  2).  High levels  of  antibodies  to  Shope 
papilloma  virus  were  found in  the  blood  of  animals  bearing  these  tumors. 
Rabbits bearing the Vx7 carcinoma, originally derived from Shope papilloma, 
also had high serum titers of neutralizing antibodies against the Shope virus, 
but the tumor itself stained poorly with fluorescent antibody preparations and 
in only a few cells. Animals bearing the Vx2 carcinoma, a  tumor also derived 
from the papillomas, had neither serum antibodies against the papilloma virus 
nor demonstrable viral antigens in the carcinoma (3-5). 
Three theories have been offered to explain the above phenomena: (a)  the 
virus did not keep up with the growth rate it had induced in the cells and was, 
as a result, diluted out; (b) the virus had been incorporated into a genome of the 
cell in a manner analogous to the lysogenic state of bacteriophage; and (c) the 
virus had entered a prolonged eclipse period within the cells and was in a form 
incapable of reacting with the viral antibody. The last two propositions encom- 
pass the phenomenon of viral masking, i.e., the presence of a protein-deficient 
virus in cells which fail to yield the infectious agent under ordinary laboratory 
conditions (2). 
Several mechanisms have been found which are operative in the viral carrier 
state (6).  Significant among these is the induction of interferon synthesis by 
the masked virus, with the consequent establishment of a  "chronic low-grade 
infection." The resistance to further viral invasion is increased in such infected 
cells and in those not yet infected but in the same interferon milieu. The demon- 
stration  of  resistance  to  superinfection  has  become  an  accepted  means  of 
detecting the viral carrier state, particularly in rubella studies (7).  Henle and 
Henle have recently reported  the release of low titers of interferon into the 
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tissue  culture  medium  overlying  Burkitt  lymphoma  lines  EB-1  and  EB-2. 
On superinfection with Newcastle disease virus, much higher  titers of inter- 
feron were produced (8). 
This paper reports the presence of viral interfering  substance, probably an 
interferon, in the protein extracts of Shope papilloma, Vx7 and Vx2  carcino- 
mas grown in vivo. 
Materials and Methods 
TumorsX.  - 
Shope  papilloma:  1 g  of stock Shope papilloma, originally taken from a  wild cottontail 
rabbit, was macerated in 10 cc of phosphate-buffered sterile saline (PBS), pH 7, and centri- 
fuged at 2000 rpm for 10 rain to remove debris. The flanks of four New Zealand rabbits were 
scarified  and coated with the virus-containing supernatant. Papillomas appeared on about 
the 12th  day and were harvested at the end of 4 wk when the tumors were large, but not 
necrotic or blood entrusted. 
Vx7 and  Vx2 carcinomas: 1 cc of  cell suspension of Vx7 at  a  concentration of  1 X  106 
cells/co was injected into the anterior and posterior thighs of three New Zealand rabbits. 
Three rabbits were similarly inoculated with Vx2. These tumors were allowed to  grow for  1 
month before harvesting, at which time they were firm,  4-5 cm in diameter, and slightly 
necrotic at the center. 
Muscle control: The anterior and posterior thigh muscles of one healthy New Zealand rabbit 
were taken for preparation of control extracts. 
Tissue  Extrc~ts.--All three tumors and the muscle were similarly prepared after aseptic 
harvesting, washing, and removing any necrotic tissue. 100 g of each tissue was cut into pieces 
of about 1 cc and homogenized in a Waring Blendor with enough sterile Earle's balanced salt 
solution (BSS), pH 7.3, to keep the suspension of broken cells fluid (150-200 cc). The homog- 
enates were then centrifuged at 2000 rpm at 8°C for 30 min until a compact pellet of cellular 
debris had been deposited at the bottom of the tubes. The supernatants were transferred to 
new centrifuge bottles and sterile ammonium sulfate (NI-I4),SO4 added to 100%  saturation 
as calculated by volume. The solutions were allowed to precipitate over a 24 hr period at 5°C. 
They were then centrifuged for 3 hr at 3000 rpm at 5°C until a discrete pellet of precipitated 
protein was formed. 
The supernatants were discarded and the pellets transferred to 18/32 Visking dialysis bags 
and dialyzed against six 1000 ec changes of Earle's BSS over an 8 hr period, thereby removing 
the (NIt,),SO4. The extracts were then dialyzed for 12 hr against 0.1 ~  KCI-HC1 acid buffer 
(/~H 2.1) at 5°C to inactivate any bacteria or virus present. Four final dialyses over a  24 hr 
period were then carried out against Earle's BSS. As a final precaution against viral or bac- 
terial contaminants, all solutions were passed through size F  Seitz filters (100/z)  and centri- 
fuged at  100,000 g for 60 min at 8°C.  The resulting supernatants were lyophilized and the 
powdered extracts made up in sterile Earle's BSS such that 1 cc contained 50 mg of extract. 
Viruses.-- 
Fibroma virus: 0.5 g of Shope fibroma was macerated in a mortar in 5 cc of sterile Ringer's 
solution. The suspension was centrifuged for 15 rain at 2000 rpm and the supernatant taken 
for assay with fibroma virus. 
Vaccinia virus: For each assay a stock lyophilized pellet of live vaccinia virus obtained from 
Wyeth Laboratories, Philadelphia, Pa.,  (Dryvax Smallpox  Vaccine)  was suspended in  1 cc 
of PBS and then diluted to either 10  -3 or I0  -4. The virus suspension was titered for primary 
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plaque-forming units on rabbit kidney monolayer cultures simultaneously with the  running 
of each assay. 
In Vivo Assay.--The papilloma protein extract was first tested in vivo for viral interfering 
activity against Shope fibroma virus. The flanks of two New Zealand rabbits were shaved 
and seven paired subcutaneous injections of fibroma virus and protein extract were given in 
various combinations. 
In Vitro Assay.--1 cc (50 rag) of protein extract was incubated with primary rabbit kidney 
monolayers for 1 hr at 37°C. Maintenance (Melulck's) medium was added and the cultures 
then challenged with vaccinia virus suspension at 10  --4 dilution. The monolayers were placed 
in a vibration-free incubator at 37°C for 48 hr at which time the medium was decanted and 
the cell layers stained with gentian violet (9). 
TABLE I 
Inhibition of Fibroma Virus In Vivo by Shope Papilloma Extract 
"ibroma virus (co). 
'apilloma extract  (rag) 
"ibroma development 
Site of injection 
A  B  C  D  E  F  G 
1  1  1  1  1  0  0 
50  37.5  25  12.5  0  50  100 
o  o  o  o  ++++  o  o 
The first assays on each extract were run as separate controlled experiments with vaccinia 
virus of varying titers from different stock pellets. Three types of flasks were set up: those 
containing only virus; those with both virus and protein extract, either tumor or control; and 
those with protein extract alone. These last flasks were observed for signs of cellular toxicity. 
In tests to obtain information on comparative potency another group of rabbits was inocu- 
lated as previously described with Shope papilloma virus, Vx7  or Vx2 cells and a new set 
of extracts were prepared. All three extracts were then assayed for viral interfering activity 
in vitro simultaneously using the same stock vaccinia virus suspension at 10  -4 dilution. The 
Shope papilloma extract was also challenged with a  lower virus dilution of 10  -z. 
RESULTS 
In Vivo Assay.--The combinations of fibroma virus,  papilloma extract, and 
the results are shown in Table I. There was an initial mild inflammatory reac- 
tion at all sites where protein extract had been injected, regardless of the pres- 
ence or absence of virus. This disappeared by the 7th day. On the 5th day firm 
subcutaneous nodules,  typical of  fibromas,  appeared  at  all four  sites  where 
virus alone had been injected (Table I, E). These reached maximum growth of 
1.5  cm diameter by day 11 and began to regress by day 14. Ulcers occurred in 
all. At no time did any nodules appear at sites where either virus and protein 
(Table I, A-D), or protein extract alone (Table I, F-G), had been injected. 
In  Vitro  Assay.--Although  the  in vivo assay indicates that  the  papilloma 
extract  did interfere with the  action of  the virus, the method itself was not 
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to  test  the  effects  of  tumor  extracts  on  viral  growth.  The  combinations  of 
vaccinia virus, protein extract,  and the results are shown in Tables II, III, and 
IV. Figures 1, 2, and 3 present the results graphically. It is evident from Table 
II and Fig. 1 that the presence of the protein extract of Shope papilloma caused 
almost complete suppression of plaque formation. The extracts of Vx7 and Vx2 
carcinomas  (Tables  III  and  IV;  Figs.  2  and  3)  caused  partial  inhibition  of 
TABLE II 
Inhib~ion  ~  PlaqueFormationbyShopePap~lomaExtract 
Flask  No. 
1-2 
3-5 
68 
9-10 
11-12 
13-14 
Vaccinia virus 
104 
104 
104 
0 
0 
0 
Muscle  extract 
mg 
0 
50 
0 
50 
0 
0 
Papilloma 
extract 
mg 
0 
0 
50 
0 
50 
0 
No. of plaques 
Average  Range 
117  111-124 
194  180-208 
1  0-3 
0  0 
0  0 
0  0 
250 
150 
0 
-~  100 
50 
:.:*:.:.:.:? 
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FIG. 1. Inhibition  of plaque formation by Shope papilloma extract. DEBORAH PAVAN LANGSTON AND  LESLIE H.  SOBIN 
TABLE III 
Inhibition  of Plaque Formation by Vx7 Extract 
891 
Flask No. 
1-2 
3-5 
6-8 
9-10 
11-12 
13-14 
Vaccinia virus 
lo4 
104 
104 
0 
0 
0 
Muscle extract 
rag 
0 
5O 
0 
50 
0 
0 
Vx7 
extract 
rag 
0 
0 
50 
0 
50 
0 
No. of plaques 
Average  Range 
135  128-143 
224  210-238 
78  66-88 
0  0 
0  0 
0  0 
250 
20(] 
150 
E  10O 
:m, 
50  ii!i!i!ii!!l 
:~:~:~:i:i:~:~:':':~ 
i~i!i~i!iiiii!!!i~i 
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FIG. 2. Inhibition of plaque formation by Vx7 carcinoma extract. 
plaque formation. The number of plaques produced in the presence of the Vx7 
extract was 65 % lower than the number produced in flasks containing control 
muscle extract. The Vx2 extract caused a  64 %  reduction in plaques. Vx2 had, 
however, been challenged with a  higher virus titer than had  the Vx7 extract. 
Monolayers exposed  to  protein extract  alone did  not differ morphologically 
from untreated controls and showed no evidence of toxicity. It was noted that 892  SHOPE PAPILLOMA  AND  VX7  AND  Vx2  CARCINOM.AS 
TABLE  IV 
Inhibition  of Plaque Formation by Vx2 Extract 
Flask No. 
1-2 
3-5 
6-8 
9-10 
11-12 
13-14 
Vaccinla virus 
10  4 
10  4 
10  4 
0 
0 
0 
Muscle extract 
rag 
0 
5O 
0 
5O 
0 
0 
Vx2 
extract 
mg 
0 
0 
50 
0 
50 
0 
No.  of plaques 
Average  Range 
296  288-305 
363  347-374 
127  109-140 
0  0 
0  0 
0  0 
500 
400 
c:z 
o 
100 
---  .  .. 
:;:::;:::;:i:i:i:: 
:~:i:i:~:!:i:~:i:!  !::'!':':';:;:::!!  Average  per cent 
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iii!iiiiiiiiiiii!i  :~:i:?:i:i:!:i:i:i  64 per cent 
!iiiiiiiiii;iiiiil  ::: 
;::::::::::::::::: 
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Fro. 3. Inhibition  of plaque formation by Vx2 carcinoma extract. 
the plaques in the tumor extract treated bottles were not only fewer in number 
than  the  controls,  but  also  approximately  one-half  to  one-third  smaller  in 
diameter. This observation is in accordance with that made by Gifford et al. in 
their work with vaccinia virus and chick embryo interferon (10). 
The per cent of virus inhibition by an extract was calculated using muscle 
for  control values as  it  was  believed that  these monolayers more  closely re- DEBORAH  PAVAN  LANGSTON  AND  LESLIE  H.  SOBIN  893 
sembled the flasks with tumor extract in that both had increased amounts of 
protein in the medium.  Comparison of the vaccinia virus plaque count  (flasks 
TABLE V 
Simultaneous Assay of Shope .Papilloma,  Vx7 and  Vx2 Extracts for Plaque Inhibition 
Flask No. 
1-5 
6-10 
11-14 
15-18 
19-22 
23-24 
25-26 
27-28 
29-30 
31-32 
Vaccini  l 
virus 
104 
10' 
10' 
104 
10-* 
0 
0 
0 
0 
0 
Muscle 
extract 
~g 
0 
50 
0 
0 
0 
5O 
0 
0 
0 
0 
Papilloma 
extract 
mg 
0 
0 
50 
0 
0 
0 
5O 
0 
0 
0 
Vx7 
extract 
mg 
0 
0 
0 
50 
0 
0 
0 
50 
0 
0 
Vx2 
extract 
mg 
0 
0 
0 
0 
50 
0 
0 
0 
50 
0 
No. of plaques 
Average  Range 
66  58-73 
76  72-82 
1  0-1 
45  41-51 
50  48-53 
0  0 
0  0 
0  0 
0  0 
0  0 
Per cent 
inhibition 
99 
40 
34 
IO0 
g 
o 
E  --i 
z20 
Vaccinia  Muscle 
virus  extract 
alone  control 
and 
virus 
34 per cent 40 per cent 
~  Average per cent 
[~:..___~iit  inhibition  compared 
I~ill  to muscle control 
f~!!t¢R  per cent 
vx2  vx7  Shope 
extract  extract  papilloma 
and  and  extract 
virus  virus  and  virus 
FIG. 4.  Simultaneous  assay of  Shope papilloma and  Vx7  and  Vx2  extracts for plaque 
inhibition. 
1  and  2),  with  the  virus-muscle  extract  plaque  count  (flasks  3-5),  clearly 
reveals the enhancing effect of the richer medium on virus action. 
The results of the individual assays indicated the presence of a  viral-inhibi- 
tory substance in all three tumor extracts. Because vaccinia virus from different 
stock pellets and of different titers had been used, it was not possible to com- 894  SFrOPE PAPILLOMA  AND  Vx7  AND  vx2  CARCINOMAS 
pare the relative potency of the extracts. To obtain this comparative informa- 
tion,  new  extracts were made up  and  assayed simultaneously with  the  same 
stock vaccinia virus  at dilution  10-4.  The results  are  shown  in  Table V  and 
Fig. 4.  There was virtually complete suppression of plaque formation in flasks 
containing the extract of Shope papilloma. The extracts from the Vx7 and Vx2 
TABLE  VI 
Incomplete Plaque Suppression  by Shope Papilloma Extract Using High  Virus Titer 
Flask No. 
1-3 
4-5 
6-8 
Vaccinia  virus 
lO-Z 
lO-~ 
lO-3 
Muscle  extract 
mg 
o 
50 
0 
Papilloma extract 
mg 
0 
0 
50 
No. of plaques 
Average  Range 
370  360-382 
671  661-682 
246  224-282 
1000 
8O0 
6o0 
E 
::7 
200 
Average per cent 
plaque  inhibition 
compared  to 
muscle control  63 per cent 
Vaccinia  Muscle  extract  Shope  papilloma 
virus  control  extract 
alone  and  virus  and  virus 
FIG. 5.  Incomplete plaque suppression by papilloma extract using high virus titer. 
carcinomas produced 40 %  and 34 %  inhibition,  respectively, compared to the 
muscle control. 
As in the individual assays, the plaques in tumor extract-containing bottles 
were smaller  than  those  in  control bottles.  Flasks  containing  protein extract 
alone did  not  differ morphologically from untreated  controls when examined 
microscopically, and showed no signs of toxicity. 
Because one characteristic of interferon is that its effect may be overcome if 
viral titers are sufficiently high, another assay was done using 10-3 virus dilution 
with papilloma protein extract which  had given almost  100 %  suppression at 
dilution of 10  -4. The results of this experiment are shown in Table VI and Fig. 5. DEBORAH  PAVAN  LANGSTON  AND  LESLIE H. SOBIN  895 
These reveal that, at a higher titer of virus, partial (63 %) rather than complete 
suppression of plaque development occurs with the Shope papilloma extract. 
The plaque-enhancing effect of the muscle extract is again seen. 
DISCUSSION 
These experiments indicate the presence of a viral interfering substance in the 
protein extracts from Shope papilloma, Vx7  and Vx2 carcinomas. The follow- 
ing  characteristics  indicate that  the  substance  is most likely an  interferon: 
(a) precipitated out with the protein fraction; (b) nondialyzable; (c) biologically 
active after being maintained at pH 2.1,  and 5°C for several hours; (d)  mor- 
phologically nontoxic to tissue cultures on microscopic examination; (e) able to 
reduce the size  and number of virus plaques produced;  (f)  overcome by high 
virus titers; and (g) not virus specific. Because the substance was active against 
the unrelated vaccinia and fibroma viruses,  it is unlikely that  this effect is 
produced by the presence of antibody. 
The greatest amount of interfering material is produced by the papilloma, 
the only growth from which good yields of infectious viru~ may be easily ob- 
tained. The Vx7 and the Vx2,  however,  appear  to produce  less  but  approxi- 
mately equal amounts of interfering material. The finding of a viral inhibiting 
substance in the Vx7 is not unexpected as this tumor has not only been shown 
to contain small amounts of capsid antigen, but also to yield nucleic acid cap- 
able of inducing typical papillomatous growths on rabbit hosts (11). Evans et al. 
have noted that growth of Vx7  carcinomas may be  suppressed  by previous 
immunization with homologous papilloma virus  (12).  There  is,  however,  no 
significant suppression of infection by papilloma viral nucleic acid in carcinoma- 
bearing  animals  (13),  implying  that  the  amount  of  interfering  substance 
produced  is not  sufficient to  prevent  further invasion by homologous viral 
DNA. 
The extraction of an interferonlike substance  from  the Vx2,  a  carcinoma 
which no longer contains detectable viral antigen and elicits no viral antibody 
production, is an unexpected finding and implies the presence of viral nucleic 
acid within the cells. The negative results of fluorescent staining  on the Vx2 
indicate only that there is no viral protein coat present and are in no way re- 
lated to the presence  or absence of viral nucleic acid. This finding of inter- 
feronlike activity contradicts the proposition that loss  of antigenicity in the 
Vx2  is secondary to the virus' being  "diluted out" of  the  system via  rapid 
tumor growth. Whether this nucleic acid is established in lysogenic form or in a 
prolonged  eclipse  state  cannot  be  determined  by  the  present  experiments. 
There have been no reported studies on the existence of viral specific  tumor 
antigens in the Vx2 carcinoma. Such studies would, of course,  further clarify 
the question of persistance of masked virus in this tumor which, somewhere 
between its 22nd and 46th passage, lost all trace of detectable virus (14). 896  SHOPE  PAPILLOMA  AND  Vx7  AND  VX2  CARCINOMAS 
Although fluorescent antibody studies reveal only rare viral protein antigen 
in the Vx7, the production of approximately equal  amounts of viral-inhibiting 
substance by the Vx7 and Vx2 indicate that viral nucleic acid is present in the 
nonfluorescing cells as well. The extraction of equal amounts of the substance 
from the Vx2 may imply that the comparatively small amount  of fluorescing 
antigen in the Vx7 has little bearing on the amount of interferonlike substance 
produced. The production of considerably more interferonlike material by the 
papilloma, however, may indicate that the virus, in appreciably greater amounts 
in its complete form, is a  greater stimulus to the production of the substance 
than is the agent in incomplete form; a  situation somewhat analogous to the 
increased interferon production by lymphoma cells in the Henles' study (8). 
S~,RY 
In vivo assay of Shope papilloma protein extract and in vitro assay of extracts 
from Shope papilloma,  Vx7  and Vx2  carcinomas showed strong interferon-like 
activity in the papilloma and moderate activity in the carcinomas. The inter- 
pretation is that the presence of viral nucleic acid in all three tumors stimulated 
the  production  of  this  substance  even  though  fluorescent  antibody  studies 
reveal the protein coat only in the papilloma and Vx7. 
The authors  gratefully acknowledge the  support  and  guidance of  Dr.  John  G.  Kidd. 
Dr.  Jack W. C. Hagstrom critically reviewed the manuscript. 
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